
# Property of [SPONSOR] Confidential

**Protocol Title:** A randomized, double-blind, placebo-controlled, parallelgroup,
multicenter study to evaluate the safety and efficacy
of secukinumab 500 mg and 250 mg in adult patients with
active psoriatic arthritis after 16 weeks of treatment
compared to placebo and to assess the safety, tolerability
and efficacy up to 52 weeks
**Protocol Number:** [PROTOCOL_NO]
**Phase:** Phase III
**Sponsor:** [SPONSOR]

## Table of Contents
1. Introduction
2. Study Objectives
3. Investigational Plan
...

## 1. Introduction
### 1.1 Background
(AI Fallback) Detailed background on ...

### 1.2 Purpose
To evaluate safety and efficacy...

## 2. Study Objectives
### 2.1 Primary Objective
To demonstrate efficacy...

## 3. Investigational Plan
### 3.1 Study Design
Auto-Inferred...

## 6. Visit Schedule and Assessments
### Table 6-1: Assessment Schedule
| Visit | Screening | Week 0 | Week 4 |
|-------|-----------|--------|--------|
| Vitals| X         | X      | X      |

## 12. References
1. Clinical Trial Protocol Template Version 03
